In This Section

Program: Wednesday, July 22

Tuesday, July 21 Thursday, July 23 Friday, July 24

Please note that this meeting will take place as an in-person event in Boston, Massachusetts and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.

*-Short talk from proffered abstract

Wednesday, July 22

Wednesday, July 22

Networking Breakfast

7-8 a.m. | Independence Ballroom West

Fireside Chat

8-8:45 a.m. | Grand Ballroom

Moderator: To be announced

  • 8 a.m. | Introduction
  • 8:05 a.m. | Fireside Chat
    Richard Pazdur

Break

8:45-9 a.m. | Grand Ballroom Prefunction

Plenary Sessions 1-2

9-11 a.m.

Plenary Session 1: Drug Discovery – Pharma vs Biotech vs Academia

Grand Ballroom
Session Chair: William Pao, Revelio Therapeutics, Inc., New York, New York

  • 9:05 a.m. | Timothy Heffernan, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 9:35 a.m. | Lilli Petruzzelli, Genentech, Inc., South San Francisco, California
  • 10:05 a.m. | James Christensen, Terremoto Biosciences, South San Francisco, California
  • 10:35 a.m. | Panel Discussion

Plenary Session 2: Technologies, Biomarkers, and Advanced Diagnostics to Guide Target Discovery and Effective Anti-cancer Therapies

Constitution Ballroom A
Session Chair: Kurt A. Schalper, Yale University, New Haven, Connecticut

  • 9:05 a.m. | Advances and impact of circulating molecular biomarkers in oncology drug development
    Maximilian Diehn, Stanford University, Stanford, California
  • 9:30 a.m. | Immunogenomic determinants of response and resistance to immune checkpoint blockade
    Kellie N. Smith, Johns Hopkins University School of Medicine, Baltimore, Maryland
  • 9:55 a.m. | High dimensional spatial molecular studies to support target discovery and de-risk therapeutics in oncology
    Kurt A. Schalper
  • 10:20 a.m. | Interpretable image analysis using advanced computational models to support therapeutic decisions in oncology
    Issam El Naqa, Moffitt Cancer Center, Tampa, Florida
  • 10:45 a.m. | Panel Discussion

Break

11-11:20 a.m. | Grand Ballroom Prefunction

Drugging the Undruggable Sessions 1-3

11:20 am-12:50 p.m.

Drugging the Undruggable Session 1: Epigenetics

Grand Ballroom
Session Chair: Johnathan R. Whetstine, Fox Chase Cancer Center, Philadelphia, Pennsylvania

  • 11:25 a.m. | New inhibitors, degraders, and stabilizers of epigenetic targets and new approaches to target undruggable proteins
    Jian Jin, Icahn School of Medicine at Mount Sinai, New York, New York
  • 11:45 a.m. | Epigenetic therapies: A path to controlling extrachromosomal DNA and rearrangements
    Johnathan R. Whetstine
  • 12:05 p.m. | Scott A. Armstong, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 12:25 p.m. | Panel Discussion

Drugging the Undruggable Session 2: Transcription Factors

Constitution Ballroom A
Session Chair: Angela N. Koehler, Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts

  • 11:25 a.m. | Proximity pharmacology and transcription factor drug discovery
    Michael A. Erb, The Scripps Research Institute, La Jolla, California
  • 11:45 a.m. | Direct targeting of the intrinsically disordered transactivation domain of androgen receptor enables transcriptome-selective pharmacology
    Marianne D. Sadar, BC Cancer Research, Vancouver, British Columbia, Canada
  • 12:05 p.m. | Kimberly Stegmaier, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 12:25 p.m. | Panel Discussion

Drugging the Undruggable Session 3: Synthetic Lethality Beyond DDR

Constitution Ballroom B
Session Chair: Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, Texas

  • 11:25 a.m. | Novel synthetic lethal targets
    Mathew J. Garnett, Wellcome Sanger Institute, Cambridge, United Kingdom
  • 11:45 a.m. | Synthetic lethality opportunities for tumors with MMEJ deficiency
    Alan D. D’Andrea, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 12:05 p.m. | Kathryn C. Arbour, Memorial Sloan Kettering Cancer Center, New York, New York
  • 12:25 p.m. | Panel Discussion

Lunch on Own

12:50-3 p.m.

Challenges in Drug Discovery Sessions 1-3

3:15-5 p.m.

Challenges in Drug Discovery Session 1: Biology

Grand Ballroom
Session Chair: Paul Workman, The Institute of Cancer Research, London, United Kingdom

  • 3:20 p.m. | Integrated bioscience solutions to drug discovery challenges
    Paul Workman
  • 3:50 p.m. | A multi-agent AI system for accurately determining drug mechanism-of-action at scale
    Jason M. Sheltzer, Stanford University, Stanford, California
  • 4:20 p.m. | ELF3-driven epigenetic reprogramming creates ERK pathway dependency in SERD-resistant ER+ breast cancer*
    Na Zhang, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 4:25 p.m. | Dark kinase dependency screening reveals STK17A as a previously unrecognized targetable vulnerability in EGFR-altered glioblastoma*
    Eric Spinetti, STARX Therapeutics, Miami, Florida
  • 4:30 p.m. | Panel Discussion

Challenges in Drug Discovery Session 2: Chemistry

Constitution Ballroom A
Session Chair: Kevan Shokat, University of California, San Francisco, California

  • 3:20 p.m. | Kevan Shokat
  • 3:50 p.m. | Kyle Seamon, Revolution Medicines, Redwood City, California
  • 4:20 p.m. | Targeting the “undruggable” oncogene CCNE1 using a molecular glue degrader in CCNE1 amplified cancers*
    Nina Ilic-Widlund, Monte Rosa Therapeutics, Boston, Massachusetts
  • 4:25 p.m. | enFoldX: AI classification of AlphaFold3-derived structural ensembles enables T cell specificity prediction*
    Jonathan Levine, Memorial Sloan Kettering Cancer Center, New York, New York
  • 4:30 p.m. | Panel Discussion

Challenges in Drug Discovery Session 3: Clinical

Constitution Ballroom B
Session Chair: Puja Sapra, AstraZeneca, Gaithersburg, Maryland

  • 3:20 p.m. | Decision making under uncertainty: What actually predicts Ph3 success… and how to improve decision making in the future
    Cristian Massacesi, Bristol Myers Squibb, Princeton, New Jersey
  • 3:50 p.m. | Delivering on precision medicine: Navigating biological purity with operational and commercial realities
    Alice T. Shaw, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 4:20 p.m. | JAB-BX600, a first-in-class EGFR-directed antibody drug conjugate delivering a novel KRAS G12D inhibitor*
    Andrea Wang-Gillam, Jacobio (US) Pharmaceuticals, Burlington, Massachusetts
  • 4:25 p.m. | Patient-level prediction of trial outcomes with a calibrated pan-cancer foundation model*
    Samantha Liang, Unlearn.AI, San Francisco, California
  • 4:30 p.m. | Panel Discussion
    Additional Panelist:
    Jennifer Euting, Patient Advocate

Break

5-5:15 p.m. | Grand Ballroom Prefunction

Spotlight on Proffered Papers Session

5:15-6 pm | Grand Ballroom

Session Chair: Patricia M. LoRusso, Yale School of Medicine, New Haven, Connecticut

  • 5:20 p.m. | Discovery of a next-generation KAT6A inhibitor with an improved therapeutic index and reduced hematotoxicity risk*
    Davide D’Alia, Qubit Pharmaceuticals, Paris, France
  • 5:25 p.m. | VBC106: A first-in-class FOLR1/MSLN targeted tri-specific antibody drug conjugate (ADC) in ovarian cancer, endometrial cancer, lung adenocarcinoma and beyond*
    Jing Li, VelaVigo (Shanghai) Limited, Shanghai, China
  • 5:30 p.m. | DLL3 CAR-T and CAR-NK cell combination therapy promotes synergistic antitumor activity in small cell lung cancer*
    Alan Bers, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 5:35 p.m. | Targeted degradation of cyclin T1 constrains transcription elongation and triggers tumour cell apoptosis*
    Janice Wenzheng Neng, University of Cambridge, Cambridge, United Kingdom
  • 5:40 p.m. | A first-in-class Pin1 degrader provides robust PKPD response and efficacy in PDAC models*
    Morgan O’Shea, Larkspur Biosciences, Cambridge, Massachusetts
  • 5:45 p.m. | GLIO-1 is a selective DHODH inhibitor that is effective in IDH-mutant gliomas and KDM6-mutated cancers*
    Diana Shi, Harvard Medical School, Boston, Massachusetts
  • 5:50 p.m. | CDK4/6 bifunctional degraders overcome CDK4/6i resistance in breast cancer and demonstrate antitumor efficacy in additional tumor types*
    Maechen Wang, Memorial Sloan Kettering Cancer Center, New York, New York

Poster Session A / exhibit show / Reception

5:15-7:45 p.m. | Back Bay Ballroom

Evening off / Dinner on own

7:45 p.m.